PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Nurtec ODT, also known as Rimegepant, was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021.

Prior to Pfizer's acquisition of the company, Biohaven knowingly caused the submission of false claims to Medicare and other federal healthcare programs by paying providers to induce them to write ...

Michigan will receive $155,930.53 in the wake of a Pfizer, Inc subsidy agreeing to pay $59.7 million --plus interest-- to resolve kickback allegations Monday.

Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023.

The settlement resolves allegations that Biohaven paid improper remuneration, including speaker honoraria and high-end restaurant meals, to physicians and other healthcare professionals to promote ...

In October 2022, Pfizer completed the acquisition of Biohaven Pharmaceutical Holding Co., the maker of Nurtec ODT, from Biohaven Pharmaceuticals Inc. for about $11.6 billion.